When the Patient Doesn't Fit the Profile: Protocols, Probability and the Duty to Look Closer

The Profile Said No; the Patient Said Look Again

Imagine you are the doctor. A young woman, a fellow health professional, has had a cough for a few weeks. She does not smoke. Lung cancer in someone like her is rare and every guideline you trained on points elsewhere. A CT scan exposes her to radiation, costs money and, for almost every patient like her, would show nothing.

Telling her to wait is not careless. It is what the evidence says. Now imagine you are her, two months later, learning that the cancer has reached your lymph nodes. Both of these are true and that is what makes this a real dilemma rather than a story about bad doctors.

Two duties pulling apart Screening guidelines exist for good reasons.

The International Agency for Research on Cancer recommends low-dose CT screening only for people aged 50 to 80 with long smoking histories. Radiation from repeated scans itself raises cancer risk and false positives lead to further tests and anxiety.

Resources are limited. A protocol built on probability protects most patients from unnecessary harm. But screening guidelines are written for people without symptoms. Rasika Bombatkar had a persistent cough that did not resolve.

At that point, the question was no longer whether to screen a low-risk population. It was whether to investigate a specific patient whose body was telling a story the profile did not predict. She has said that doctors should at least review such decisions when symptoms are present.

The easy answer would be that the doctors simply erred. But the honest answer is harder. Doctors who order scans for every young person with a cough would expose many to radiation and cost for very few findings. The question is where the line should be and who bears the cost when it is drawn in the wrong place.

The second barrier:

money Diagnosis was only the first obstacle. Molecular testing cost Rs 50,000 to Rs 1 lakh. The targeted drug osimertinib cost about Rs 1 lakh a month against her salary of Rs 35,000. She missed a clinical trial by one sub-stage, 3b instead of 3a.

She survived by buying an unbranded Bangladeshi version for Rs 25,000 a month, relying on patent flexibilities available there and on her own monitoring of side effects. Here too the protocol, a price set by patent and a trial set by stage, worked as designed and still excluded her.

Where

I land The resolution is to keep protocols but limit what they govern. Population screening guidelines should decide who is screened when well. They should not decide whether a symptomatic patient's persistent complaint is investigated.

Once symptoms persist, clinical judgment and the duty of care must override the risk profile and the patient's own account deserves weight even when it does not fit the expected pattern. This choice has a cost. More young patients will get scans that turn out normal, with some radiation and expense.

That cost is worth bearing, because the alternative is a system that is right on average and wrong for the people outside the average.

For the exam, the insight is this: evidence-based protocols serve populations; ethics demands attention to the individual in front of you. A good public servant or doctor, knows when a rule's purpose has stopped matching the case.